Standard BioTools Inc. (NASDAQ:LAB) Shares Sold by Swiss National Bank

Swiss National Bank lowered its stake in Standard BioTools Inc. (NASDAQ:LAB) by 6.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 437,960 shares of the company’s stock after selling 32,000 shares during the period. Swiss National Bank owned approximately 0.12% of Standard BioTools worth $766,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in Standard BioTools by 7.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock valued at $270,000 after buying an additional 9,995 shares during the period. HighTower Advisors LLC raised its holdings in Standard BioTools by 13.0% during the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock worth $162,000 after purchasing an additional 10,690 shares in the last quarter. Wolverine Trading LLC acquired a new stake in Standard BioTools in the third quarter valued at about $27,000. Simon Quick Advisors LLC purchased a new stake in Standard BioTools in the 4th quarter valued at approximately $54,000. Finally, SG Americas Securities LLC increased its position in Standard BioTools by 34.2% during the 4th quarter. SG Americas Securities LLC now owns 135,927 shares of the company’s stock worth $238,000 after purchasing an additional 34,670 shares during the period. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

Separately, KeyCorp downgraded Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Standard BioTools Price Performance

Shares of LAB opened at $1.14 on Friday. Standard BioTools Inc. has a 52-week low of $0.99 and a 52-week high of $3.04. The company has a 50-day simple moving average of $1.32 and a 200-day simple moving average of $1.68. The company has a market capitalization of $432.04 million, a PE ratio of -1.61 and a beta of 1.62.

Insiders Place Their Bets

In other news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the firm’s stock in a transaction on Friday, February 28th. The shares were bought at an average cost of $1.06 per share, for a total transaction of $5,110,216.54. Following the completion of the transaction, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This trade represents a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 53.10% of the stock is currently owned by company insiders.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.